-
1
-
-
77954761574
-
Contemporary post surgical management of differentiated thyroid carcinoma
-
Tala H, Tuttle RM Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010, 22:419-429.
-
(2010)
Clin Oncol (R Coll Radiol)
, vol.22
, pp. 419-429
-
-
Tala, H.1
Tuttle, R.M.2
-
2
-
-
33747642244
-
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
-
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2892-2899
-
-
Durante, C.1
Haddy, N.2
Baudin, E.3
-
3
-
-
84055184770
-
Approach to the patient with advanced differentiated thyroid cancer
-
Schlumberger M, Sherman SI Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012, 166:5-11.
-
(2012)
Eur J Endocrinol
, vol.166
, pp. 5-11
-
-
Schlumberger, M.1
Sherman, S.I.2
-
4
-
-
2442568538
-
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas
-
Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:2414-2420.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2414-2420
-
-
Puxeddu, E.1
Moretti, S.2
Elisei, R.3
-
5
-
-
33845255290
-
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture
-
Santoro M, Melillo RM, Fusco A RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006, 155:645-653.
-
(2006)
Eur J Endocrinol
, vol.155
, pp. 645-653
-
-
Santoro, M.1
Melillo, R.M.2
Fusco, A.3
-
6
-
-
0034714190
-
PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma
-
Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
-
(2000)
Science
, vol.289
, pp. 1357-1360
-
-
Kroll, T.G.1
Sarraf, P.2
Pecciarini, L.3
-
7
-
-
0036277892
-
Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation
-
Tuttle RM, Fleisher M, Francis GL, Robbins RJ Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002, 87:1737-1742.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 1737-1742
-
-
Tuttle, R.M.1
Fleisher, M.2
Francis, G.L.3
Robbins, R.J.4
-
8
-
-
0037102369
-
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
-
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
-
(2002)
Cancer Res
, vol.62
, pp. 4645-4655
-
-
Wedge, S.R.1
Ogilvie, D.J.2
Dukes, M.3
-
9
-
-
0037115405
-
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
-
Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284-7290.
-
(2002)
Cancer Res
, vol.62
, pp. 7284-7290
-
-
Carlomagno, F.1
Vitagliano, D.2
Guida, T.3
-
10
-
-
23844544081
-
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
-
Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16:1391-1397.
-
(2005)
Ann Oncol
, vol.16
, pp. 1391-1397
-
-
Holden, S.N.1
Eckhardt, S.G.2
Basser, R.3
-
11
-
-
33846844387
-
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
-
Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006, 1:1002-1009.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 1002-1009
-
-
Tamura, T.1
Minami, H.2
Yamada, Y.3
-
12
-
-
84655175698
-
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
-
Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
-
(2012)
J Clin Oncol
, vol.30
, pp. 134-141
-
-
Wells, S.A.1
Robinson, B.G.2
Gagel, R.F.3
-
13
-
-
46449117698
-
Motesanib diphosphate in progressive differentiated thyroid cancer
-
Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42.
-
(2008)
N Engl J Med
, vol.359
, pp. 31-42
-
-
Sherman, S.I.1
Wirth, L.J.2
Droz, J.P.3
-
14
-
-
50649095801
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a Phase II study
-
Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a Phase II study. J Clin Oncol 2008, 26:4708-4713.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4708-4713
-
-
Cohen, E.E.1
Rosen, L.S.2
Vokes, E.E.3
-
15
-
-
77957359933
-
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
-
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972.
-
(2010)
Lancet Oncol
, vol.11
, pp. 962-972
-
-
Bible, K.C.1
Suman, V.J.2
Molina, J.R.3
-
16
-
-
72949106263
-
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
-
Hoftijzer H, Heemstra K, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009, 161:923-931.
-
(2009)
Eur J Endocrinol
, vol.161
, pp. 923-931
-
-
Hoftijzer, H.1
Heemstra, K.2
Morreau, H.3
-
17
-
-
34248177447
-
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach
-
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007, 31:1256-1264.
-
(2007)
Am J Surg Pathol
, vol.31
, pp. 1256-1264
-
-
Volante, M.1
Collini, P.2
Nikiforov, Y.E.3
-
18
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
19
-
-
79956029711
-
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study
-
Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011, 33:315-327.
-
(2011)
Clin Ther
, vol.33
, pp. 315-327
-
-
Zhang, L.1
Li, S.2
Zhang, Y.3
-
20
-
-
84863197764
-
Vandetanib: in medullary thyroid cancer
-
Frampton JE Vandetanib: in medullary thyroid cancer. Drugs 2012, 72:1423-1436.
-
(2012)
Drugs
, vol.72
, pp. 1423-1436
-
-
Frampton, J.E.1
-
21
-
-
0032757213
-
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
-
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
-
(1999)
Eur J Cancer
, vol.35
, pp. 1773-1782
-
-
Young, H.1
Baum, R.2
Cremerius, U.3
-
22
-
-
70449529019
-
Discrete sequential boundaries for clinical trials
-
Lan KK, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
-
(1983)
Biometrika
, vol.70
, pp. 659-663
-
-
Lan, K.K.1
DeMets, D.L.2
-
23
-
-
50649095250
-
Phase II trial of sorafenib in advanced thyroid cancer
-
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4714-4719
-
-
Gupta-Abramson, V.1
Troxel, A.B.2
Nellore, A.3
-
24
-
-
40949130884
-
A phase II study of gefitinib in patients with advanced thyroid cancer
-
Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18:317-323.
-
(2008)
Thyroid
, vol.18
, pp. 317-323
-
-
Pennell, N.A.1
Daniels, G.H.2
Haddad, R.I.3
-
25
-
-
66149139452
-
From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors
-
Wahl RL, Jacene H, Kasamon Y, Lodge MA From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(suppl 1):122S-150S.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
26
-
-
0038352143
-
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response
-
Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003, 21:2574-2582.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2574-2582
-
-
Erasmus, J.J.1
Gladish, G.W.2
Broemeling, L.3
|